1. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS. (12th June 2019) Authors: Leonard, J.; Trneny, M.; Izutsu, K.; Fowler, N.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C.; Gribben, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study. (June 2017) Authors: Fowler, N.; Gopal, A.K.; Schuster, S.J.; Trotman, J.; Hess, G.; Hou, J.; Yacoub, A.; Lill, M.; Martin, P.; Vitolo, U.; Spencer, A.; Radford, J.; Jurczak, W.; Morton, J.; Osmanov, D.; Caballero, D.; Deshpande, S.; Vermeulen, J.; Damle, R.; Schaffer, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CLINICAL IMPLICATIONS OF CYTOPENIAS BEYOND DAY 30 AFTER AXI‐CEL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Strati, P.; Adkins, S.; Nastoupil, L.; Westin, J.; Hagemeister, F.; Fowler, N.; Lee, H.J.; Fayad, L.; Samaniego, F.; Ahmed, S.; Varma, A.; Arafat, S.; Johncy, S.; Kebriaei, P.; Mulanovich, V.E.; Ariza Heredia, E.; Neelapu, S.S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) – PHASE II TRIAL. (12th June 2019) Authors: Jain, P.; Romaguera, J.; Nomie, K.; Zhang, S.; Wang, L.; Oriabure, O.; Wagner‐Bartak, N.; Zhang, L.; Hagemeister, F.; Samaniego, F.; Westin, J.; Ju Lee, H.; Nastoupil, L.; Iyer, S.; Parmar, S.; Ok, C.; Kanagal‐Shamanna, R.; Chen, W.; Thirumurthi, S.; Santos, D. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. COMPREHENSIVE ANALYSIS OF PROGNOSTIC FACTORS, OUTCOMES AND MUTATION PROFILE IN PATIENTS WITH AGGRESSIVE HISTOLOGY (BLASTOID/PLEOMORPHIC) OR TRANSFORMED MANTLE CELL LYMPHOMA. (12th June 2019) Authors: Jain, P.; Kanagal‐Shamanna, R.; Zhang, S.; Ok, C.; Nogueras Gonzalez, G.; Gonzalez‐Pagan, O.; Ghorab, A.; Boddu, P.; Chen, W.; Lee, H. Ju; Nomie, K.; Fayad, L.; Westin, J.; Nastoupil, L.; Patel, K.; Ahmed, S.; Iyer, S.P.; Parmar, S.; Champlin, R.; Neelapu, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 238 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. DIFFUSE LARGE B CELL LYMPHOMA WITH SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT: CAN MRI PATTERN HELP PREDICTING OUTCOME?. (12th June 2019) Authors: Dabaja, B.; Gule‐Monroe, M.; Gunther, J.R.; Milgrom, S.; Sheu, T.; Nair, R.; Ahmed, S.; Steiner, R.; Strati, P.; Nastoupil, L.; Neelapu, S.; Pinnix, C.; Fowler, N. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 442 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA. (12th June 2019) Authors: Dickinson, M.; Popplewell, L.; Kolstad, A.; Ho, P.J.; Teshima, T.; Dreyling, M.; Schuster, S.; Thieblemont, C.; Ghosh, M.; Riedell, P.; Yateman, N.; Lehnhoff, K.; Lawniczek, T.; Pacaud, L.; Fowler, N. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN‐LABEL, PHASE II STUDY. (June 2017) Authors: Nastoupil, L.J.; Westin, J.; Fowler, N.; Fanale, M.; Samaniego, F.; Oki, Y.; Obi, C.; Cao, J.; Cheng, X.; Ma, M.; Wang, Z.; Chu, F.; Feng, L.; Zhou, S.; Davis, R.E.; Neelapu, S.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. IBRUTINIB WITH RITUXIMAB (IR) AND SHORT COURSE R‐HYPERCVAD/MTX IS VERY EFFICACIOUS IN PREVIOUSLY UNTREATED YOUNG PTS WITH MANTLE CELL LYMPHOMA (MCL). (12th June 2019) Authors: Wang, M.; Jain, P.; Zhang, S.; Nomie, K.; Wang, L.; Oriabure, O.; Nogueras Gonzales, G.; Zhang, L.; Wagner‐Bartak, N.; Hagemeister, F.; Samaniego, F.; Westin, J.; Lee, H.J.; Nastoupil, L.; Ok, C.; Kanagal‐Shamanna, R.; Chen, W.; Thirumurthi, S.; Santos, D.; Badillo, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA. (23rd June 2022) Authors: Dickinson, M.; Martinez-Lopez, J.; Jousseaume, E.; Anjos, C.; Yang, H.; Chai, X.; Wang, T.; Ramos, R.; Lobetti-Bodoni, C.; Schuster, S.; Fowler, N. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1001 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗